Fundamental, Clinical and Translational Cancer Research.
The Cancer Research Center Groningen (CRCG) was established in 2012. The aim is to translate fundamental insights in oncogenesis and tumour behaviour from basic research into cancer prevention, improvement of early detection of cancer, and better treatment for cancer patients.

The mission of the CRCG is to clarify the molecular mechanisms that determine malignant transformation in a broad spectrum of tumors and to translate these fundamental insights into improved early detection and treatment of cancers. This will ultimately lead to personalized cancer therapy, thus reducing the unintended side effects of treatment on normal tissues and improving the quality of life of cancer survivors.

The CRCG was founded in 2012 as an independent research institute of the University Medical Center Groningen. Four key research programmes have been established:

1. Damage and Repair in Cancer Development and Cancer Treatment (DARE);
2. Guided Treatment in optimal Selected cancer patientsTranslational and Clinical research in Oncology (GUTS);
3. Stem cells, Aging, Leukemia and Lymphoma (SALL);
4. TARgeted Gynaecologic Oncology  (TARGON).

These programmes are supported by 60 PIs and 139 PhD or MD/PhD students who participate in the UMCG’s Graduate School of Medical Sciences (GSMS). The various programs are characterized by a strong interaction between basic and translational research programs, as shown by joint research meetings and projects.